

## Scientific Program

Friday, 7 September 2018

SY1	Symposium
<b>9:00 – 10:30</b>	
<b>Room A (3F Shinsho Hall)</b>	
<b>New viewpoints of the amyloid cascade hypothesis</b>	
<i>Chairs: Takashi Kudo, Department of Mental Health Promotion, Osaka University Graduate School of Medicine, Japan Kohji Mori, Department of Psychiatry, Osaka University Graduate School of Medicine, Japan</i>	

- SY1-1 Making the Final Cut: Pathogenic Amyloid- $\beta$  Peptide Generation by  $\gamma$ -Secretase**  
*Harald Steiner, Biomedical Center (BMC), Metabolic Biochemistry, Ludwig-Maximilians-University Munich, Germany*
- SY1-2 Pseudo- $\gamma$ -secretase inhibitor function of Semagacestat**  
*Masayasu Okochi, Department of Psychiatry, Osaka University Graduate School of Medicine, Japan*
- SY1-3 Targeting APP substrate binding of  $\gamma$ -secretase as potential therapeutic approach for Alzheimer's disease**  
*Akio Fukumori, Department of Aging Neurobiology, National Center for Geriatrics and Gerontology, Japan*
- SY1-4 Essential involvement of plexin-B3+ oligodendrocyte precursor cells in the pathogenesis of sporadic Alzheimer's disease**  
*Yoshitaka Tatebayashi, Affective Disorders Research Project, Tokyo Metropolitan Institute of Medical Science, Japan*

SY5	Symposium
<b>10:30 – 12:00</b>	
<b>Room A (3F Shinsho Hall)</b>	
<b>New CANMAT and ISBD Guidelines for Management of Patients with Bipolar Disorders</b>	
<i>Chairs: Michael Berk, School of Medicine, Faculty of Health, Deakin University, Australia Lakshmi Yatham, Department of Psychiatry, University of British Columbia, Canada</i>	

- SY5-1 CANMAT and ISBD 2018 Guidelines for Management of Bipolar Disorder**  
*Lakshmi Yatham, Department of Psychiatry, University of British Columbia, Canada*
- SY5-2 Controversies in evidence for treatment guidelines and future directions**  
*Michael Berk, School of Medicine, Faculty of Health, Deakin University, Australia*
- SY5-3 There is an App For That: Translation and Implementation Strategies for the 2018 CANMAT and ISBD Bipolar Guidelines**  
*Ayal Schaffer, Department of Psychiatry, University of Toronto, Canada*
- SY5-4 CANMAT and ISBD 2018 Guidelines for management of patients with Bipolar Disorders: A perspective from Japan**  
*Tadafumi Kato, Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Center for Brain Science, Japan*

PL-1	Plenary Lecture
<b>12:00 – 12:45</b>	
<b>Room A (3F Shinsho Hall)</b>	
<b>Dissecting our mind based on evolutionary conservation</b>	
<i>Chair: Takeo Yoshikawa, Center for Brain Science, RIKEN, Japan</i>	

- PL-1 Dissecting our mind based on evolutionary conservation**  
*Hitoshi Okamoto, Lab. for Neural Circuit Dynamics of Decision Making, RIKEN Center for Brain Science, Japan*

**LS-1**
**Luncheon Seminar**

12:50 – 14:20

Room A (3F Shinsho Hall)

**Schizophrenia in 2018: An Overview of Cognitive Function and Metabolic Syndrome in Antipsychotics**
*Chair: Masatoshi Takeda, Cognitive Reserve Research Center, Osaka Kawasaki Rehabilitation University, Japan*
*Co-sponsor: Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd.*
**LS1-1 Welcome and introduction**
*Manit Srisurapanont, Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Thailand*
**LS1-2 Risks and benefits of pharmacological treatment of schizophrenia across lifespan**
*Xin Yu, National Clinical Research Center for Mental Disorders, Peking University Sixth Hospital, Institute of Mental Health, and the Key Laboratory of Mental Health, Ministry of Health, Peking University, China*
**LS1-3 Cognition in schizophrenia: Evaluation and optimization for best functional outcomes?**
*Eric Chen, Department of Psychiatry, The University of Hong Kong, Hong Kong*
**LS1-4 Decreasing metabolic cardiovascular risk in patients with schizophrenia: Interventions and future directions**
*Shih-Ku Lin, Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taiwan*
**PL-2**
**Plenary Lecture**

14:30 – 15:15

Room A (3F Shinsho Hall)

**Do Atypical Antipsychotic Drugs Improve Positive, Negative and Cognitive Symptoms by Modifying Synaptic Abnormalities and Restoring Synaptic Function?**
*Chair: Shigenobu Kanba, Department of Neuropsychiatry, Kyusyu University Graduate School of Medical Sciences, Japan*
**PL-2 Do Atypical Antipsychotic Drugs Improve Positive, Negative and Cognitive Symptoms by Modifying Synaptic Abnormalities and Restoring Synaptic Function?**
*Herbert Meltzer, Department of Psychiatry and Behavioral Sciences, Northwestern University, USA*
**SY9**
**Symposium**

15:15 – 16:45

Room A (3F Shinsho Hall)

**Glutamate and mood disorders**
*Chairs: Tetsuro Ohmori, Department of Psychiatry, Tokushima University, Japan*
*Yongyong Shi, Bio-X Institute, Shanghai Jiao Tong University, China*
**SY9-1 Trans-ancestry Genetic Studies of Roles of Glutamate Pathways in Schizophrenia and Mood Disorders**
*Yongyong Shi, Bio-X Institute, Shanghai Jiao Tong University, China*
**SY9-2 Elevated glutamate levels in blood in mood disorders**
*Shusuke Numata, Department of Psychiatry, Graduate School of Biomedical Sciences, Tokushima University, Japan*
**SY9-3 <sup>1</sup>H-magnetic resonance spectroscopy study of Glutamate-related abnormality in bipolar disorder**
*Masahito Nakataki, Department of Psychiatry, Tokushima University Hospital, Japan*



## SY2

## Symposium

9:00 – 10:30

Room B (3F Conference Room 1)

**Inter-Asia/Pacific collaborations on MRI studies in schizophrenia**

*Chairs: Kiyoto Kasai, Department of Neuropsychiatry, The University of Tokyo, Japan  
Michio Suzuki, Department of Neuropsychiatry, University of Toyama, Japan*

- SY2-1 Neuroimaging biomarkers to predict future transition to psychosis in individuals with an at-risk mental state using structural MRI: multi-center and international collaborations**  
*Yoichiro Takayanagi, Department of Neuropsychiatry, University of Toyama, Japan*
- SY2-2 Altered thalamo-cortical connectivity in patients with schizophrenia: A proposal for Inter-Asia/Pacific collaboration study**  
*Minah Kim, Department of Psychiatry, Seoul National University, Republic of Korea*
- SY2-3 White Matter Abnormalities in Never-Treated Patients with Long Term Schizophrenia**  
*Su Lui, Department of Radiology, West China Hospital of Sichuan University, China*
- SY2-4 Outcome, biological markers and cost in drug naïve patients with schizophrenia----a prospective study in Taiwan**  
*Yen Kuang Yang, Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Taiwan*

## SY6

## Symposium

10:30 – 12:00

Room B (3F Conference Room 1)

**Developmental pharmacology of psychotropic drugs - Basic and clinical perspective -**

*Chairs: Toru Nishikawa, Department of Psychiatry and Behavioral Sciences, Tokyo Medical and Dental University, Japan  
Edward Felix Domino, Department of Pharmacology, University of Michigan, USA*

- SY6-1 Benzodiazepine-resistant status epilepticus in children: Alteration in GABAAR signal in children and its potential preventive measure**  
*Tomohiro Morio, Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Japan*
- SY6-2 Developmental changes in the clinical effects of SSRIs and other antidepressants**  
*Takuya Saito, Department of Child and adolescent Psychiatry, Graduate School of Medicine, Hokkaido University, Japan*
- SY6-3 Postnatal development of behavioral and molecular effects of psychostimulants**  
*Toru Nishikawa, Department of Psychiatry and Behavioral Sciences, Tokyo Medical and Dental University, Japan*
- SY6-4 Developmental Pharmacology of Ketamine, Its Enantiomers, and Metabolites**  
*Edward Felix Domino, Department of Pharmacology, University of Michigan, USA*

SS1	Scientific Session
15:15 – 16:05	Room B (3F Conference Room 1)
<b>Animal Model/Molecular Neurobiology/Genetics</b>	
<i>Chairs: Masanari Itokawa, Center of Medical Research Cooperation, Tokyo Metropolitan Institute of Medical Science, Japan</i>	
<i>Roshan R. Naik, Lee Kong Chian School of Medicine, Neurobiology of Aging and Disease Laboratory, Nanyang Technological University, Singapore</i>	

- SS1-1 An investigation regarding the causal effect of interleukin-18-deficient condition on hippocampal abnormalities and depression-like behavioral changes**  
*Kyosuke Yamanishi, Department of Neuropsychiatry, Hyogo College of Medicine, Japan*
- SS1-2 Translocator protein knockout mice: an animal model of posttraumatic stress disorder?**  
*Roshan R. Naik, Lee Kong Chian School of Medicine, Neurobiology of Aging and Disease Laboratory, Nanyang Technological University, Singapore*
- SS1-3 The influence of preanalytical conditions on the cerebrospinal fluid proteome measured with an aptamer-based assay**  
*Kotaro Hattori, Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Japan*
- SS1-4 Development of cellular disease models of bipolar disorder and schizophrenia: Pedigree-based induced pluripotent stem cell studies in the Ryukyu Islands**  
*Gakuya Takamatsu, Department of Molecular and Cellular Physiology, Graduate School of Medicine, University of the Ryukyus, Japan*
- SS1-5 Association Of Social Support With DRD4 And DAT Genes In Male Population 25-64 Years: WHO Program MONICA-Psychosocial**  
*Valery Gafarov, Collaborative Laboratory of Cardiovascular Diseases Epidemiology, NIITPM- Branch of Institute of Cytology and Genetics SB RAS, Russian Federation*

SY3	Symposium
9:00 – 10:30	Room C (3F Conference Room 2)
<b>New insights from genomics and proteomics in mental health disorders: Relating genetic and protein markers to neuropathological alterations and treatment strategies</b>	
<i>Chairs: Tetsufumi Kanazawa, Department of Neuropsychiatry, Osaka Medical College, Japan</i>	
<i>Gursharan Chana, Centre for Neural Engineering, The University of Melbourne, Australia</i>	

- SY3-1 Beyond the robust genetic architecture of schizophrenia**  
*Tetsufumi Kanazawa, Department of Neuropsychiatry, Osaka Medical College, Japan*
- SY3-2 Potential biomarkers of Alzheimer's disease**  
*Carlos M Opazo, Melbourne Dementia Research Centre, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Australia*
- SY3-3 Genetic discovery of mood disorders: Can genetics elucidate the pathophysiology of mood disorders?**  
*Shuken Boku, Department of Psychiatry, Kobe University Graduate School of Medicine, Japan*
- SY3-4 From Genetic Discovery to Underlying Neurobiology in Autism Spectrum Disorder (ASD): Focus on Neuroinflammation and Glutamatergic Dysregulation**  
*Gursharan Chana, Centre for Neural Engineering, The University of Melbourne, Australia*

<b>SY7</b>	<b>Symposium</b>
<b>10:30 – 12:00</b>	<b>Room C (3F Conference Room 2)</b>
<b>Electroconvulsive Therapy in Major Psychiatric Disorders</b>	
<i>Chairs: Yong Sik Kim, Department of Psychiatry, Dongguk University Ilsan Hospital, Republic of Korea Hiroshi Yoneda, Department of Neuropsychiatry, Osaka Medical College, Japan</i>	

- SY7-1 ECT in major psychiatric disorders: the Korean experience**  
*In Won Chung, Neuropsychiatry, Dongguk University, Republic of Korea*
- SY7-2 Seizure threshold and the half-age method in bilateral ECT for Japanese patients**  
*Kazuyuki Yasuda, Department of Neuropsychiatry and Clinical Ethics, Faculty of Medicine, University of Yamanashi, Japan*
- SY7-3 ECT in the treatment of Schizophrenia: The Singapore Experience**  
*Phern-Chern Tor, Department of Mood and Anxiety, Institute of Mental Health Singapore, Singapore*
- SY7-4 Prevention of relapse after a response to ECT in major psychiatric disorders in Japan**  
*Minoru Takebayashi, Department of Neuropsychiatry, Faculty of Life Sciences, Kumamoto University, Japan*

<b>SS2</b>	<b>Scientific Session</b>
<b>15:15 – 16:35</b>	<b>Room C (3F Conference Room 2)</b>
<b>Childhood and Adolescent Disorders/Consultation and Liaison Psychiatry</b>	
<i>Chairs: Hiroaki Kawasaki, Department of Psychiatry Faculty of Medicine, Fukuoka University, Japan Chun-Hung Chang, Department of Psychiatry, China Medical University Hospital, Taiwan</i>	

- SS2-1 Autism traits: phenotypic overlap between Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD) in Chinese population**  
*Lu Hua Chen, Department of Psychology, The Chinese University of Hong Kong, China*
- SS2-2 Relationship between prefrontal cortex activity during task execution and ADHD symptoms of adult patients, and their changes by atomoxetine**  
*Atsunori Sugimoto, Department of Community Psychiatric Medicine, Niigata University Graduate School of Medical and Dental Sciences, Japan*
- SS2-3 Personality disorder is associated with low quality of life among Australian women with mental state disorders**  
*Bianca E Kavanagh, IMPACT Strategic Research Centre, School of Medicine, Deakin University, Australia*
- SS2-4 Afebrile Gap: Association with Psychopathology, Aetio-Pathogenesis and Nosological Implications of an Innovative Observation**  
*Balram Pandit, School of Medical Sciences, CMNHS, Fiji National University, Fiji*
- SS2-5 Delirium prevention from sleep-wake cycle improvement**  
*Kotaro Hatta, Department of Psychiatry, Juntendo University Nerima Hospital, Japan*
- SS2-6 Mental health, quality of life, and their predictor in patients with differentiated thyroid cancer before and after radioactive iodine treatment**  
*Te-Chang Changchien, Department of Psychiatry, E-Da Hospital, Taiwan*
- SS2-7 Severe Hepatic Outcome in Schizophrenic Patients with Viral Hepatitis: a Retrospective Nationwide Cohort Study**  
*Chun-Hung Chang, Department of Psychiatry, China Medical University Hospital, Taiwan*
- SS2-8 Osteoporosis in schizophrenic patients**  
*Nan-Ying Chiu, Department of psychiatry, Lugang Christian Hospital, Taiwan*

**Scientific Program**
**Friday, 7 September 2018**

SY4	Symposium
9:00 – 10:30	Room D (3F Conference Room 3)
<b>Comprehension of cognitive function and social cognition of schizophrenia; clinical and biological back ground</b>	
<i>Chairs: Yuji Ozeki, Department of Psychiatry, Dokkyo Medical University School of Medicine, Japan Katja Koelkebeck, Department of Psychiatry and Psychotherapy, University of Muenster, Germany</i>	

- SY4-1 Relationships between peripheral amino acid alterations and symptoms of schizophrenia including neurocognitive dysfunction**  
*Yuji Ozeki, Department of Psychiatry, Dokkyo Medical University School of Medicine, Japan*
- SY4-2 Cognitive dysfunction in schizophrenia and other psychiatric disorders: potential role of inflammation**  
*Hiroaki Hori, Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, Japan*
- SY4-3 Thought disorder and abnormal semantic representation in schizophrenia brain**  
*Yukiko Matsumoto, Department of Psychiatry, Kyoto University Graduate School of Medicine, Japan*
- SY4-4 Social cognition in schizophrenia-specification of deficits and biological background**  
*Katja Koelkebeck, Department of Psychiatry and Psychotherapy, University of Muenster, Germany*

SY8	Symposium
10:30 – 12:00	Room D (3F Conference Room 3)
<b>Asian Network of Bipolar Disorders</b>	
<i>Chairs: Shigenobu Kanba, Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyusyu University, Japan Kyooseb Ha, Department of Psychiatry, Seoul National University, Republic of Korea</i>	

- SY8-1 Brain image markers in bipolar disorder: a systemic review**  
*Yuan-Hwa Chou, Center for Quality Management and Department of Psychiatry, Taipei Veterans General Hospital, Taiwan*
- SY8-2 Neurophysiological findings in patients with bipolar disorder**  
*Naoya Oribe, Hizen Psychiatric Center, Japan*
- SY8-3 Development of multiple proteomic marker panel and predictive model for the onset and progress of major psychiatric disorders**  
*Kyooseb Ha, Department of Psychiatry, Seoul National University, Republic of Korea*
- SY8-4 Trace Lithium and Mental Health**  
*Takeshi Terao, Department of Neuropsychiatry, Oita University Faculty of Medicine, Japan*

SY10	Symposium
15:15 – 16:45	Room D (3F Conference Room 3)
<b>Current Perspectives on Immunology and Psychiatry</b>	
<i>Chairs: Andi Jayalangkara Tanra, Psychiatry, Hasanuddin University, Indonesia Tsuyoshi Miyaoka, Psychiatry, Shimane University, Japan</i>	

- SY10-1 Schizophrenia and Neuroinflammation : An Animal Model**  
*Erlын Limoa, Department of Psychiatry, Hasanuddin University, Indonesia*



## Scientific Program

Friday, 7 September 2018

- SY10-2 Development of pharmaceutical care for schizophrenia with immunological dysfunction:  
A preclinical study**  
*Arata Oh-Nishi, Division of Immune-Neuropsychiatry, Faculty of Medicine, Shimane University, Japan*
- SY10-3 Bone marrow transplantation may cure schizophrenia**  
*Tsuyoshi Miyaoka, Department of Psychiatry, Shimane University, Japan*